 |
|
|
|||||
Nifty has surged 10% from its April low, reaching 24,461, prompting experts to advise caution on lumpsum investments due to expected volatility. SIPs remain the preferred route for long-term investors, while staggered allocations via STPs are suggested for those with funds. Auto, international, and tech sector funds have shown double-digit gains since April, driven by strong earnings and global tailwinds.
Category:
News and Media
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
Category:
News and Media
DCM Shriram's shares surged by 10.5% following a robust Q4 FY25 performance, with net profit soaring 51.9% to Rs 178.9 crore. Revenue climbed 19.9% to Rs 2,876.7 crore, driven by strong segment results and improved EBITDA margins of 14.1%. The board has proposed a final dividend of Rs 3.40 per share.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||